



## Astrom Biosciences, Inc. Announces Date of 2010 Annual Meeting of Shareholders

ANN ARBOR, Mich., Aug. 2, 2010 (GLOBE NEWSWIRE) -- Astrom Biosciences, Inc. (Nasdaq:ASTM) today announced that it currently plans to hold its 2010 Annual Meeting of Shareholders on October 21, 2010. Shareholders of record as of August 26, 2010 are entitled to notice of and to vote at the 2010 Annual Meeting of Shareholders.

### About Astrom Biosciences

Astrom Biosciences is developing expanded autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Astrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Astrom's website at [www.aastrom.com](http://www.aastrom.com).

The Astrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3663>

This document contains forward-looking statements, including without limitation, statements concerning clinical trial plans, objectives and expectations, clinical activity timing, intended product development, disease treatment and progression, patient symptoms and responses to treatment, treatment options and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Astrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward-looking statements reflect management's current views and Astrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

CONTACT: Berry & Company  
Media contact  
Stephen Zoegall  
212 253-8881  
[szoegall@berrypr.com](mailto:szoegall@berrypr.com)

Astrom Biosciences  
Investor contact  
Kimberli O'Meara  
734 930-5777  
[ir@aaastrom.com](mailto:ir@aaastrom.com)

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.